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The aryl hydrocarbon receptor (AHR) is known for its role in
the adaptive and toxic responses to a large number of en-
vironmental contaminants, as well as its role in hepatovascular
development. The classical AHR pathway involves ligand binding,
nuclear translocation, heterodimerization with the AHR nuclear
translocator (ARNT), and binding of the heterodimer to dioxin
response elements (DREs), thereby modulating the transcription
of an array of genes. The AHR has also been implicated in
signaling events independent of nuclear localization and DNA
binding, and it has been suggested that such pathways may play
important roles in the toxicity of 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD). Here, we report the generation of a mouse
model that expresses an AHR protein capable of ligand binding,
interactions with chaperone proteins, functional heterodimeriza-
tion with ARNT, and nuclear translocation, but is unable to bind
DREs. Using this model, we provide evidence that DNA binding is
required AHR-mediated liver development, as Ahr
dbd/dbd mice
exhibit a patent ductus venosus, similar to what is seen in Ahr
2/2
mice. Furthermore, Ahr
dbd/dbd mice are resistant to TCDD-
induced toxicity for all endpoints tested. These data suggest that
DNA binding is necessary for AHR-mediated developmental and
toxic signaling.
Key Words: aryl hydrocarbon receptor; dioxin; TCDD; ductus
venosus.
The aryl hydrocarbon receptor (AHR)
1 is a basic helix-
loop-helix (bHLH)-per-ARNT-sim (PAS) protein that mediates
the toxic response to an array of lipophilic environmental toxi-
cants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
Thoseresponsesincludethymicinvolution,liverhypertrophy,tu-
mor promotion, epithelial hyperplasia, and teratogenesis (Poland
and Knutson, 1982). The generation of an Ahr-null allele in mice
has also provided evidence that the receptor plays an important
role in mammalian development (Gonzalez and Fernandez-
Salguero, 1998; Schmidt et al., 1996). Characterization of the
Ahr-null mouse revealed a transient microvesicular steatosis in
perinatal hepatocytes, prolonged extramedullary hematopoiesis,
and a reduced relative liver size throughout life. Recent evidence
has shown that Ahr-null mice fail to resolve a fetal vascular
structure, the ductus venosus (DV), which may be the underlying
causeofliveratrophy.Theseoutcomesaresuggestiveofarolefor
theAHRinvascularbiologyorhematopoiesisduringmammalian
development (Lahvis et al., 2000; Walisser et al., 2005).
In response to xenobiotic agonists, the AHR functions as
a ligand-activated transcription factor. Upon binding agonists
such as TCDD, the AHR translocates from the cytoplasm to the
nucleus, where it dimerizes with another bHLH-PAS protein
known as the AHR nuclear translocator (ARNT) (Hankinson,
1995). This heterodimeric complex recognizes dioxin response
elements (DREs), which regulate the transcription of a battery
of genes encoding xenobiotic metabolizing enzymes (XMEs).
These XMEs include Phase I enzymes such as Cytochromes
P450 1A1, 1A2, and 1B1, as well as the Phase II enzymes,
GST-Ya, and UDPGT (reviewed in Hankinson, 1995; Schmidt
et al., 1996).
Although the mechanism for AHR-mediated transcriptional
activation of XMEs is well-established, it has been difﬁcult to
link speciﬁc target genes to most TCDD-induced toxic
responses. Similarly, null alleles of three known transcriptional
targets of AHR, Cytochromes P450 1a1, 1a2, and 1b1, have
not been reported to possess any of the same phenotypes of
Ahr
 /  mice (Buters et al., 1999; Liang et al., 1996; Pineau
et al., 1995). This latter observation suggests that none of the
most responsive AHR target genes play an individual role in
the developmental signaling of the AHR.
Our inability to link DRE-regulated genes to most aspects of
TCDD toxicity or AHR developmental biology has led to the
developmentofanumberofmodelswhichproposethattheAHR
takes part in important signaling events that are independent of
DRE binding or even ARNT dimerization. Included in this
list of models is the hypothesis that the ligand-activated AHR
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as cSrc kinase, the retinoblastoma protein (Rb), and RelA
(Blankenship and Matsumura, 1997; Enan and Matsumura,
1996; Ge and Elferink, 1998; Puga et al., 2000). Similarly, it has
been proposed that TCDD toxicity may occur as a result of the
activated AHR sequestering available ARNT in the cell. In
in vitro and cell culture model systems, the capacity of an
activated AHR to reduce ARNT participation in hypoxia signal
transduction has been demonstrated and has also been
challenged (Berghard et al., 1993; Chan et al., 1999; Gradin
et al., 1996; Pollenz et al., 1999).
The various proposals suggesting that AHR may be involved
in cellular signal transduction mechanisms independent of
interactions with ARNT or DREs has led to a complicated
picture of the mechanism of AHR-mediated development and
TCDD toxicity. In an effort to test the role of DRE-independent
signaling by the AHR in these processes, we have developed
mouse models with deﬁciencies in speciﬁc signaling steps. We
have shown previously that nuclear translocation of the AHR is
required for normal liver development and TCDD-induced
toxicity in mice (Bunger et al., 2003). Through the use of
a similar gene-targeting approach, we have now generated
a mouse line that expresses a mutant Ahr that is unable to bind
DREs. We present evidence which suggests that the binding of
AHR to DREs is required for developmental processes as well
as AHR-mediated toxicity in vivo.
MATERIALS AND METHODS
Oligonucleotides and expression constructs. Oligonucleotides were
synthesized by Invitrogen (Carlsbad, CA) and are designated as follows:
  OL659: 5#-ATCCAGAAGAGCTTATCAGTGGTTCTGC-3#
  OL941: 5#-CTGAGGGGACGTTTTAATG-3#
  OL942: 5#-AACATTTGCACTCATGGATAG-3#
  OL1352: 5#-GGTACCTCTGAGTTCAAGTCTAGTCTG-3#
  OL1353: 5#-GGTACCGCATGCTTACTAGTAGTTTTTCTAG-3#
  OL1503:5#-GCCACCATGAGCAGCGGCGCCAACATCACCTATGC-
CAGCCGCAAGCGGCGCAAGCCGGTGCAGAAAACAG-
TAAAGCCCGGGCCCGCTGAA-3#
  OL1793:5#-GTAAAGCCCGGGCCCGCTGAAGGAATTAAGT-
CAAATCCTTCTAAGCGACACAGAGGATCCGACCGGCTGAACA-
CAGAGTTAGA-3#
  OL2639:5#-ACTAGTCGACCTAACCCATTTGCTGTCCACCAGT-
CATGCTAGCCATACTCTGCACCTTGCTTAG-3#
PL65 and PL613 were described previously (Carver et al., 1998; Jain et al.,
1994). To generate the pTgTAHRT7 (PL1550) construct, PL65 was used as
a template for 22 rounds of PCR ampliﬁcation using OL1503 (forward) and
OL2639 (reverse). The oligo, OL1503, contains a consensus ‘‘Kozak start site’’
and a mutation creating an SrfI restriction site that replaces the isoleucine at
position 25 (I25) with glycine in the AHR coding region. The oligonucleotide,
OL2639, contains the region of AHR cDNA preceding the stop codon as well
as a sequence for the T7-epitope and a translational stop. The pTgtAHRdbdT7
(PL1548) construct was generated by two-step PCR using PL65 as a template.
In step 1, the forward oligo was OL1793, which contains the GGATCC
insertion mutation, and the reverse oligo was OL2639. The product of the ﬁrst
step was then used as a template for 20 rounds of ampliﬁcation using OL1503
and OL2639. Sequencing of all constructs was performed to ensure that no
mutations were randomly generated. The plasmid, PL256, is a luciferase
reporter driven by a DRE-containing promoter element from the upstream
region of the CYP1A1 gene (DRE-luc) (Postlind et al., 1993).
Protein analysis. All western blot analyses, gel-shift, and photoafﬁnity
labeling experiments were performed essentially as described (Carber and
Bradﬁeld, 1997; Chan et al., 1999; Jain et al., 1994; Poland et al., 1991, 1986,
1994). In vitro protein expression was carried out using a transcription/
translation system reticulocyte lysate system (Promega, Madison, WI).
Microsomes were isolated from approximately 0.5 g of mouse liver which
was homogenized in ice-cold MENG buffer (25mM 4-morpholinepropanesul-
fonic acid pH7.5, 0.025% wt/vol sodium azide, 1mM ethylene glycol bis(2-
aminoethyl ether)tetraacetic acid, 10% glycerin vol/vol or glycerol) followed by
two centrifugation steps at 10,000 3 g and 100,000 3 g. The microsomal pellet
was resuspended in 250 ll of 15mM Tris-Cl pH8/250mM sucrose.
Ethoxyresoruﬁn O-deethylase (EROD) assays were performed in a 96-well
format. In each well, 3 ll of 0.1mM ethoxyresoruﬁn and 20 ll of 5mM NADPH
were mixed with 5 ll of the total microsomal prep in 200 ll in MENG buffer.
Following incubation at 25C for 10 min, the production of hydroxyresoruﬁn
was measured using a ﬂuorimeter (fMax, Molecular Devices, Sunnyvale, CA) at
510-nm excitation and 590-nm emission. Total protein concentrations were
determined using the bicinchoninic acid assay (Pierce, Rockford, IL). Units are
expressed as relative ﬂuorescence/minute/mg protein (RFU/min/mg protein) as
calculated using SoftMax Pro software (Molecular Devices).
Coimmunoprecipitation (Co-IP) experiments were performed by incubating
approximately 10 fmol of reticulocyte lysate–expressed proteins with 5 lg
antibody in 500 ll of cold MENG buffer supplemented with 15mM NaCl,
0.1mM dithiotreitol, and 0.1% NP-40. Bound protein-antibody complexes were
precipitated with either protein A-sepharose (Sigma, St Louis, MO) or
T7-antibody-coupled agarose (Novagen, La Jolla, CA) for 1.5 h at 4C, washed
four times with cold MENG buffer, eluted in 23 sodium dodecyl sulfate (SDS)
sample buffer, and analyzed by polyacrylamide gel electrophoresis (PAGE).
Cell culture conditions and treatments. Embryonic stem (ES) cells,
designated GS-1, were purchased from Genome Systems (St Louis, MO). The
ES cells were cultured on a conﬂuent layer of mouse embryonic ﬁbroblasts
derived from PGK-NeoR transgenic mice (The Jackson Laboratory, Bar
Harbor, ME) in Dulbecco’s modiﬁed Eagle medium (DMEM)-high glucose
supplementedwith20%fetal bovineserum (HyClone,Logan,UT),0.1mM non-
essential amino acids, 2mM L-glutamine, 10mM 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), 100 U/ml penicillin, 100 lg/ml streptomycin,
and 1000 U/ml ESGRO (Invitrogen). To generate Ahr
 /  ﬁbroblasts,
heterozygous Ahr
 /  mice, which were previously backcrossed to C57BL/6J
for 16 generations, were intercrossed to generate littermate þ/þ, þ/ , and  / 
littermate embryos. Following isolation of embryos from their yolk sacs, the
heads and livers were removed by dissection. DNA was isolated from each
individual embryo and was used for genotyping as described below. At passage
2, þ/þ and  /  ﬁbroblasts were placed on a 3T3 protocol and maintained on
this protocol until passage 25 (Nilausen and Green, 1965). Cells were grown in
DMEM-high glucose and supplemented with 10% fetal bovine serum, 0.1mM
nonessential amino acids, 2mM L-glutamine, 10mM HEPES, 100 U/ml
penicillin, and 100 lg/ml streptomycin. At passage 28, individual clones were
isolated from each genotype, maintained in the same media and passaged
regularly at subconﬂuence. Transient transfections were performed using
Fugene-6 (Roche, Palo Alto, CA) with 1 lg total DNA and a 3:1 Fugene-
6:DNA ratio. When TCDD was used, cells were allowed to recover for one day
after transfection and 1nM TCDD in dimethyl sulfoxide (DMSO) was added
directly to the media (at a ﬁnal DMSO concentration of 0.1% vol/vol).
Immunoﬂuorescence was performed as described previously using a high-
afﬁnity rabbit polyclonal antibody raised against recombinant AHR (BEAR-3)
and a ﬂourescein isothiocyanate (FITC)–conjugated goat anti-rabbit secondary
antibody (Jackson Immunochemicals, West Grove, PA) (Jain et al., 1994).
Mammalian 2-hybrid analysis. The ‘‘bait’’ expression construct, PL283,
contains a Gal DNA-binding domain fusion of ARNT, which is also deleted for
the transactivation domain (Jain et al., 1994). The plasmid, PGL5 (Promega,
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sequences (UAS) upstream of an SV40 minimal promoter and the luciferase
gene. A green ﬂuorescence protein expression construct (Clontech, Mountain
View, CA) was used as a control for transfection efﬁciency. Brieﬂy, equal
amounts of plasmids pTgTAHRdbd (PL1548) or pTgTAHRs (PL1550) were
cotransfected with PL283 and the pGL5 reporter. These cells were treated with
1nM TCDD and luciferase assays were performed using The Luciferase Assay
kit (Promega) and read on a luminometer.
Generation of Ahr
dbd/dbd mice. A 15-kb region of homology surrounding
exon 2 of Ahr was isolated from a 129SvJ genomic library (Genome Systems)
as described (Schmidt et al., 1993, 1996). A six nucleotide insertion
(GAATTC) was introduced into exon 2 by megaprimer PCR using OL1793
and OL942. This product was used as a reverse megaprimer for PCR with
OL659. An SphI fragment from this PCR product was used to replace exon 2 in
an 8-kb BamHI genomic fragment. A 5.5-kb region containing the mutated
exon 2 was ampliﬁed with OL1352 and OL1353 and cloned into the KpnI site
of ploxPNT (Tybulewicz et al., 1991). A 7-kb SphI fragment from the 5# region
of exon 2 was cloned into the NotI/XhoI site of this construct to generate the
ﬁnal targeting construct, designated PL1238.
Ten micrograms of the targeting construct was electroporated into GS1 ES
cells (Genome Systems) and selection was performed using 200 lg/ml G418
and 1mM Ganciclovir. Clones were screened by Southern blot on BamHI-
digested genomic DNA using a probe 3# to the end of the targeting construct
(PL311). Correctly targeted clones were injected into 3.5-day postcoital
C57BL/6J blastocysts, and the resulting chimeras were backcrossed to C57BL/
6J to determine the contribution of the ES clones to the germline. Mice were
genotyped using the PCR primers, OL941 and OL942. PCR was carried out for
40 cycles (95C, 30$;6 0 C, 30$;7 2 C, 2#) in buffer containing 3.5mM MgCl2.
A BamHI digest cuts the 380-bp PCR product from the targeted Ahr
dbd allele
into two fragments of 240 and 140 bp, which were detected on a 2% agarose
gel. Removal of the neomycin cassetted inserted into the Ahr locus as part of the
gene-targeting process was performed by breeding Ahrdbd/dbd mice at N6 to
CMV-Cre/tg mice. The F2 generation was genotyped for the presence of the
neomycin cassette by PCR. Animals where neomycin was successfully removed
were then backcrossed three generations to C57BL/6 (Ahr
dbd/dbd, Floxed).
Animals. Animals were housed in a selective pathogen-free facility on
corn cob bedding with food and water ad libitum according to the rules and
guidelines set by the University of Wisconsin—Madison Animal Care and Use
Committee. Where appropriate, animals were injected once i.p. with p-dioxane
alone or with 100 lg/kg TCDD in p-dioxane. After 6 days, animals were
weighed and sacriﬁced by cervical dislocation and organs were immediately
removed and weighed. Tissues for histopathological analysis were ﬁxed in 10%
neutral-buffered formalin and embedded in parafﬁn wax. Five or 10-lm
sections were stained with hematoxalin and eosin (H&E) or Oil Red-O and
hematoxalin. For angiography, 1 ml of Omnipaque 300 (Nycomed, Inc.,
Princeton, NJ) was injected into the hepatic portal vein post mortem.
Continuous X-ray images were obtained over a period of 10 s using an OEC
9800 Portable Vascular C-ARM (Medical Systems, Inc., Salt Lake City, UT).
Patent DV was also scored by trypan blue perfusion. Statistical analyses were
performed using Student’s t-test. For induction of cleft palate, pregnant dams
were i.p. injected with either DMSO or 128 lg TCDD/kg body weight on
embryonic day 10 (ED10). Litters were scored for the presence of cleft palate
and hydronephrosis on ED17–18.
RESULTS
Characterization of the AHRdbd Protein In Vitro
A mutant AHR cDNA, designated ‘‘AHRdbd,’’ was
generated by the insertion of nucleotides GGTACC, coding
for amino acids glycine and serine, between arginine-39 (R39)
and aspartate-40 (D40) of the wild-type AHR cDNA (Fig. 1).
Expression of the recombinant AHRdbd protein in rabbit
reticulocyte lysate produced a protein approximately 95 kDa,
in accordance with the known size of the wild-type protein.
Photoafﬁnity labeling experiments indicated that the AHRdbd
protein bound ligand with a capacity and afﬁnity that was
similar to its wild-type counterpart (data not shown). The DRE
binding properties of AHRdbd were analyzed by a gel-shift
protocol. Neither AHR nor AHRdbd proteins interacted
signiﬁcantly with a
32P-labeled DRE oligonucleotide in the
absence of ARNT or in the presence of ARNT when an agonist
was not present. The addition of the agonist, b-napthoﬂavone
(BNF), induced formation of the AHR/ARNT/DRE complex,
but not the AHRdbd/ARNT/DRE complex (Fig. 2A).
Co-IP experiments were utilized to determine whether the
AHRdbd protein retains the ability to interact with HSP90 and
ARA9. An HSP90-speciﬁc antibody was capable of pre-
cipitating both
35S-labeled AHR and AHRdbd, and to the same
degree (Fig. 2B). Furthermore, T7-peptide antibody-coupled
agarose beads equally precipitated
35S-labeled ARA9 when
incubated in the presence of T7-tagged AHR and T7-tagged
AHRdbd (Fig. 2C). Together, these results indicate that
AHRdbd is capable of interacting with ligand, HSP90, and
ARA9 in a manner similar to the wild-type AHR, but is not
capable of interacting with DREs.
Characterization of AHRdbd Signaling in Ahr
 /  Fibroblasts
To determine whether the AHRdbd could signal effectively
in cell culture, we performed transient transfections of AHR or
AHRdbd with a DRE-driven luciferase reporter in immortal-
ized Ahr
 /  3T3 ﬁbroblasts. Upon transfection of wild-type
AHR cDNA, luciferase activity increased relative to cells
transfected with reporter alone. This response was enhanced
2.5-fold by exposure of the cells to 1nM TCDD. In
comparison, luciferase activity in cells transfected with
AHRdbd did not increase upon exposure of cells to TCDD
(Fig. 3A).
Indirect immunoﬂuorescence analysis was used to determine
the subcellular localization of AHRdbd. Ahr
 /  3T3 ﬁbroblasts
were transiently transfected with AHR or AHRdbd cDNAs and
FIG. 1. Schematic of the functional domains of the AHR protein. The
enlarged portion depicts the GS insertion between the last residue of the basic
domain and the ﬁrst residue of the HLH domain, thereby introducing a BamHI
restriction site.
ARYL HYDROCARBON RECEPTOR DNA-BINDING DOMAIN MUTANT 85visualized using a BEAR3 primary antibody and a FITC-
conjugated secondary antibody. The AHR was found to
localize to the cytosol in untreated ﬁbroblasts, but localized
to the nucleus within2ho ftreatment with 1nM TCDD.
Interestingly, the AHRdbd protein is constitutively nuclear in
the absence of ligand, and localization was not altered by
treatment with 1nM TCDD (Fig. 3B).
AHRdbd Interacts with ARNT in a Mammalian 2-Hybrid
Assay
To determine whether AHRdbd functionally interacts with
ARNT, we performed a mammalian two-hybrid analysis using
Gal4-ARNT-DTAD as ‘‘bait’’ and the full-length AHRdbd
as ‘‘ﬁsh.’’ Cotransfection of wild-type AHR with the Gal4-
ARNT-DTAD along with a Gal4UAS-luciferase reporter
showed a slight increase in RLU over reporter alone. Exposure
to 1nM TCDD increased luciferase activity threefold. Cotrans-
fection of the AHRdbd construct with the Gal4-ARNT-DTAD
and reporter also slightly increased luciferase activity over cells
with reporter alone and showed a 10-fold increase in luciferase
activity after TCDD treatment (Fig. 3C).
Generation and Characterization of Ahr
dbd/dbd Mice
We used a megaprimer PCR approach to insert a GGATCC
sequence (encoding Proline-Arginine) immediately down-
stream of the basic region of exon 2 in a 15-kb region of
homologous genomic DNA derived from the Ahr locus
(Fig. 4A). The ﬁnal targeting construct, ploxPNT/AHR
dbd,
was electroporated into GS-1 ES cells (Genome Systems) and
selected in both G418 and Ganciclovir (Roche). Double-
selected clones (150 total) were screen by Southern blot and
ﬁve correctly-targeted clones were identiﬁed. One clone gave
rise to a chimera that transmitted the Ahr
dbd allele to the
germline. The resulting Ahr
dbd/dbd Targeted allele mice were
genotyped by PCR and restriction digest (Fig. 4B). To generate
the Floxed allele mice, the neomycin cassette was excised by
breeding to CMV-Cre mice, and the resulting offspring were
genotyped by PCR. All Cre-positive mice were negative for
neo. The N3F1 mice were born at the expected frequency
(Fig. 4C) and were fertile. Western blot analysis of liver protein
extracts from Ahr
dbd/dbd (Targeted and Floxed) mice and wild-
type littermates was used to quantify the relative in vivo
expression levels of the AHRdbd protein, and showed that
although the Targeted allele produced hypomorphic expression
of the Ahr
dbd protein as compared with wild-type littermates,
the amount of protein produced in the Floxed mice was
equivalent to wild-type littermates (Fig. 4D).
Characterization of AHRdbd Signaling In Vivo
To determine whether AHRdbd signals effectively in vivo,
Ahr
dbd/dbd (Floxed) and wild-type mice were injected in-
traperitoneally with 100 lg/kg TCDD. After 6 days, liver
microsomes were isolated and analyzed for EROD activity.
Microsomes from wild-type mice showed a low basal EROD
activity that was induced 10-fold by TCDD. In contrast,
microsomes from Ahr
dbd/dbd mice showed extremely low basal
EROD activity, which was unaltered by TCDD treatment,
indicating that AHRdbd lacks the ability to activate gene
transcription from DRE elements in vivo (Fig. 5).
Ahr
dbd/dbd (Floxed) Mice Exhibit Developmental Defects
Similar to Ahr
 /  Mice
Wild-type and Ahr
dbd/dbd mice were examined for the
developmental phenotypes found previously in Ahr
 /  mice
(Fernandez-Salguero et al., 1996, 1997; Gonzalez and
Fernandez-Salguero, 1998; McDonnell et al., 1996; Schmidt
et al., 1996; Lahvis and Bradﬁeld, 1998; Lahvis et al., 2000;
Peters et al., 1999; Zaher et al., 1998). Tissue wet weights were
determined for liver, spleen, heart, thymus, and testis of
8-week-old male Ahr
dbd/dbd and wild-type littermates. Similar
to Ahr-null mice, the Ahr
dbd/dbd mice were found to exhibit
FIG. 2. Biochemical analysis of AHRdbd recombinant protein. (A)
electromobility shift assay analysis of AHRdbd. AHR, ARNT, and AHRdbd
proteins were expressed in reticulocyte lysate and equal quantities were
incubated with a
32P-labeled, double-stranded oligo containing a single DRE
consensus sequence. Shift of the AHR/ARNT heterodimer was induced by
coincubation with 10lM BNF. An AHR-Ab was included to block the complex
formation, controlling for speciﬁcity. (B,C) Co-IP of AHRdbd with HSP90.
Wild-type or AHRdbd
35S-labeled in vitro–translated proteins were coincu-
bated with reticulocyte lysate and HSP90-speciﬁc antibody (Ab) or preimmune
IgG. Complexes were precipitated with Protein A-sepharose beads, separated
on a 7.5% SDS-PAGE gel, and visualized with autoradiography. (D) Co-IP
of AHRdbd with ARA9. T7-tagged AHR and AHRdbd were incubated with
35S-labeled ARA9. Complexes were precipitated using T7 antibody-coupled
agarose beads and separated on a 7.5% SDS-PAGE gel.
86 BUNGER ET AL.25% smaller livers than wild-type littermate controls. Con-
versely, the hearts and spleens were 25 and 58% larger,
respectively, in these animals (p < 0.005, Fig. 6A).
Histopathological analysis of livers taken from Ahr
dbd/dbd mice
at postnatal days (PND) 7, 14, and 21 revealed a transient
microvesicular steatosis around PND 7, which resolved by
PND 14, and appeared identical to livers from age-matched
Ahr
 /  mice (Fig. 6B and data not shown). Histopathological
analyses were also performed on adult spleen, heart, thymus,
testis, lung, colon, kidney, eye, and brain, but revealed no
signiﬁcant differences between Ahr
dbd/dbd and wild-type mice
(data not shown). These ﬁndings are consistent with those
reported in our previous work characterizing the Ahr
 /  mouse
(Schmidt et al., 1996).
A consistent phenotype found in all Ahr
 /  mice is the
presence of a ductous venosus (DV) throughout life (Lahvis
et al., 2005). To determine whether Ahr
dbd/dbd mice exhibit
a patent DV, the ﬂow of contrast medium through the perfused
liver was observed with the use of serial angiograms. In a wild-
type littermate, contrast medium ﬂowed into the portal vein and
immediately into the portal branches of the liver (Fig. 6C).
After ﬁlling the major branching veins of the liver, contrast
entered the suprahepatic inferior vena cava (IVC) and then
ﬂowed retrograde, ﬁlling the infrahepatic IVC. However, in the
Ahr
dbd/dbd mice, contrast ﬂowed directly from the portal vein to
the IVC. The DV in the Ahr
dbd/dbd mouse was clearly visible as
a short segment that runs perpendicular to both the portal vein
and the IVC. Trypan blue perfusion was also used to score for
a patent DV. Whereas 0% of wild-type mice (0/6) showed a
patent DV, 100% (6/6) of Ahr
dbd/dbd mice scored positive for
this structure, a vascular pattern consistent with the frequency of
patent DV seen in Ahr
 /  mice (Fig. 6D) (Lahvis et al., 2000).
Ahr
dbd/dbd Mice are Resistant to TCDD-Induced Toxicity
To determine the importance of DNA binding in the AHR-
mediated physiologic response to TCDD, 4-week-old male
Ahr
dbd/dbd mice, wild-type littermates, and Ahr
þ/  mice were
treated with 100 lg/kg TCDD. Mice were sacriﬁced 6 days
later and assayed for hepatomegaly and thymic involution, two
classic endpoints associated with TCDD toxicity in these
animals. In response to TCDD, the Ahr
þ/þ mice (n ¼ 10)
showed a 23% increase and 59% decrease in liver and thymus
weights, respectively (p < 0.001; Figs. 7A and 7B). The Ahr
þ/ 
(n ¼ 11) mice showed a 16% increase in liver weight (p < 0.001)
FIG. 3. Cellular characterization of the AHRdbd protein. (A) Luciferase
assay for DRE-driven transcription. Ahr
 /  3T3 ﬁbroblasts were transfected
with equal amounts of DRE-Luc (PL256) and either AHR or AHRdbd
recombinant cDNAs. Cells were then treated with 1nM TCDD (black bars) or
0.1% DMSO alone (white bars) for 24 h. Values represent relative luciferase
units normalized to total protein levels. (B) Subcellular localization of
AHRdbd. Indirect immunoﬂuorescence was used to identify the subcellular
localization of AHRdbd in Ahr
 /  3T3 ﬁbroblasts transiently transfected with
either Ahr
þ/þ or Ahr
dbd/dbd. Prior to staining, nuclear translocation was induced
by exposure of cells to 1nM TCDD for 2 h prior to staining. (C) Mammalian
2-hybrid analysis of AHRdbd interactions. The schematic diagram depicts the
reporter construct (pG5luc), the ‘‘bait’’ construct (Gal-ARNT), and the ‘‘ﬁsh’’
construct (AHR), showing the amino acid sequence of the basic region in wild-
type (wt) and AHRdbd (dbd) recombinant proteins. The two-hybrid analysis
was carried out using equal amounts (0.33 lg) of transiently transfected Gal-
ARNT and either wild-type AHR or AHRdbd, followed by incubation with
0.1% DMSO or 1nM TCDD. Values are expressed as relative luciferase units
(*p < 0.001).
ARYL HYDROCARBON RECEPTOR DNA-BINDING DOMAIN MUTANT 87and a 51% decrease in thymus weight 6 days after TCDD
exposure (p < 0.001). In contrast, the Ahr
dbd/dbd mice (n ¼ 10)
showed no signiﬁcant difference in liver or thymus weights
(p ¼ 0.52, and p ¼ 0.97, respectively), mimicking the response
seen in Ahr
 /  mice (Schmidt et al., 1996).
TCDD is known to cause intrahepatic lipid accumulation in
Ahr wild-type but not Ahr
 /  mice (Poland and Knutson, 1982;
data not shown). We therefore qualitatively examined the
presence of lipids in Ahr
dbd/dbd mice by Oil Red-O staining. As
expected, TCDD caused a signiﬁcant increase in hepatic lipid
content in Ahr
þ/þ mice, and Ahr
þ/  mice accumulated lipid to
the same degree. However, similar to Ahr
 /  mice, Ahr
dbd/dbd
mice were resistant to the effects of TCDD and did not
accumulate lipid (data not shown and Fig. 7C).
As TCDD is a potent teratogen, we sought to determine
whether Ahr
dbd/dbd mice were resistant to TCDD-induced cleft
palate and hydronephrosis. Whereas 29% (10/35) of wild-type
embryos (ED17–18) exhibited cleft palate upon TCDD
treatment, Ahr
dbd/dbd embryos were completely resistant
(0/52). Similarly, 100% (35/35) of wild-type mice exhibited
TCDD-induced hydronephrosis, but Ahr
dbd/dbd mice were
entirely resistant (0/52; Table 1).
DISCUSSION
Several reports have suggested that AHR-DRE binding may
not be a requirement for TCDD signaling and toxicity
(Blankenship and Matsumura, 1997; Enan and Matsumura,
1996; Ge and Elferink, 1998; Puga et al., 2000). The
implication of these models is that the AHR may signal in
a toxicologically relevant manner through protein interactions
in the cytosolic or nuclear compartment. In this regard, it has
been reported that the cytosolic cSrc protein tyrosine kinase
becomes activated in response to TCDD in cell-free extracts of
guinea pig adipose tissue and mouse NIH3T3 cells (Enan and
FIG. 4. Generation of Ahr
dbd mice. (A) Schematic diagram depicting the
targeting construct used to generate the Ahr
dbd allele in mice. Restriction
enzyme sites shown are Mlu (M), BglII (Bg), BamHI (B), and SrfI( S ) .
Arrowheads ﬂanking the neomycin resistance cassette (Neo-R) indicate the
location of LoxP sites. Shown in gray boxes are the locations of the Neo-R
cassette, including the phosphoglycerate kinase promoter (p), the bHLH domain,
and the Herpes Simplex Virus thymidine kinase gene cassette (HSV-tk). Primers
used for PCR genotyping are shown (OL941 and OL942) as well as the location
of the Southern probe used to genotype ES cells for recombination. The Floxed
allele was generated by crossing the Ahr
dbd Targeted allele animals to an animal
expressing the Cre-recombinase protein driven by the CMV promoter, and the
subsequent outcrossing to C57BL/6J to eliminate the Cre transgene. (B) PCR-
based genotyping of Ahrþ/þ, dbd/dbd, and þ/dbd mice. The ampliﬁed product
from OL941 and OL942 is cut by BamHI only when the targeted allele is
present. (C) Western blot analysis. AHR protein expression in liver extracts
from wild-type and Ahr
dbd/dbd mice. Lane 1: Floxed allele (Neo excised); lane 2:
Targeted allele (Neo present); lane 3: Ahr
þ/þ (1/4 protein concentration); lane 4:
Ahr
þ/þ (1/2 protein concentration); lane 5: Ahr
þ/þ.
FIG. 5. EROD analysis of liver microsomes from Ahr
dbd/dbd mice. Wild-
type 129SV/J and Ah
dbd/dbd mice were administered a single injection of
p-dioxane (-) or 32 lg/kg TCDD in p-dioxane (þ) and sacriﬁced after 24 h.
Microsomes were isolated from 0.5 g of liver, and EROD activity was
quantiﬁed.
88 BUNGER ET AL.Matsumura, 1996). This interaction was shown to be dependent
on AHR, as activity was lower in AHR-immunodepleted
extracts. An interaction of AHR with the retinoblastoma
protein (pRB) has also been proposed. The AHR was shown to
be immunoprecipitated in rat hepatoma 5L cells by antibodies
to pRB, but in yeast and cell-free interaction analysis, only
truncated forms of AHR showed signiﬁcant interactions. In
a second study, this interaction was reported to be important in
G1 cell-cycle arrest and occurred only after ligand-bound AHR
translocated to the nucleus (Ge and Elferink, 1998; Puga et al.,
2000). A third proposed mechanism through which AHR may
mediate toxicity is through a repression of NF-jB. Experiments
in vitro and in cell culture have shown that AHR-NF-jB
interactions may occur through direct binding of AHR and the
RelA subunit (Tian et al., 1999). We and others have
considered the notion that cross-talk occurs between the
AHR and HIF-1a signaling pathways via their common
dimerization partner, ARNT, the underlying idea being that
TCDD toxicity may be the result of ARNT sequestration rather
than AHR-ARNT-DRE interactions (Berghard et al., 1993;
Chan et al., 1999; Gradin et al., 1996; Pollenz et al., 1999).
We hypothesized that if any of these models were correct,
then related toxic responses to TCDD should occur in animal
models harboring a correctly folded AHR protein with
a mutation that prevents its binding to the DRE. Such a mutant
should be capable of sequestering ARNT, as well as interacting
with cSrc, pRB, and NF-jB, and yet be unable to activate
transcription of DRE-driven genes. We therefore used
homologous recombination to replace the endogenous bHLH
region of the Ahr locus with a bHLH region carrying both an
I25G mutation (SrfI site) and a GS insertion (BamHI site) at
amino acid residue 39. This type of insertion mutation was
generated with the idea that it would effectively shift the basic
region out of the major groove of DNA without disrupting the
dimerization capability of the HLH domain or the overlapping
nuclear localization signal (Bacsi and Hankinson, 1996; Ikuta
et al., 1998). Upon construction of the corresponding mutant
cDNA, we found that the AHRdbd protein does in fact form
a robust, ligand-inducible interaction with the ARNT protein in
a ligand dependent manner using mammalian two-hybrid
analysis. Moreover, the resulting protein binds ligand and
interacts with its known cellular chaperones, Hsp90 and
ARA9. In keeping with our predicted impact on function, the
AHRdbd protein was incapable of forming an AHRdbd/
ARNT/DRE complex in a gel-shift analysis. Surprisingly, we
found that although this mutation did not change amino acids
thought to be directly involved in nuclear localization, it did
appear to target the protein constitutively to the nuclear
compartment. Although this ﬁnding implicates a disruption in
ARA9- and HSP90-AHR interactions, Co-IP experiments
demonstrate that these interactions were similar to those seen
with wild-type AHR. Moreover, our two-hybrid experiments
indicated that the AHRdbd still bound similar amounts of
agonist upon exposure in cell culture.
In order to test the ability of Ahr
dbd/dbd mice to signal in
classical xenobiotic adaptation pathways, we quantiﬁed EROD
activity following TCDD exposure. We found that Ahr
dbd/dbd
mice failed to show an increase in EROD activity in response
FIG. 6. Developmental phenotype of Ahr
dbd/dbd mice. (A) Relative organ wet weights of Ahr
dbd/dbd mice (white bars) and wild-type littermates (black bars)
sacriﬁced at 8 weeks of age (n ¼ 5). *Indicates p < 0.01 by Student’s t-test (wild-type versus Ahr
dbd/dbd). (B) Representative H&E sections of livers from 7-day-old
wild-type (littermate), Ahr
dbd/dbd, and Ahr
 /  mice (403 magniﬁcation). (C) Time-lapse angiography of wild-type (top row) and Ahr
dbd/dbd (bottom row)
littermates. Arrows identify key features as follows: BV, branching vessel; PV, portal vein; shIVC, suprahepatic inferior vena cava; ihIVC, infrahepatic inferior
vena cava. Total time elapsed from the ﬁrst panel to the last is approximately 10 s. (D) Incidence of patent DV in wild-type and Ahr
dbd/dbd male mice as measured
by trypan blue perfusion.
ARYL HYDROCARBON RECEPTOR DNA-BINDING DOMAIN MUTANT 89to TCDD, indicating that DRE-mediated transcriptional events
are eliminated in these mice. We also assayed for several of the
known developmental defects observed in Ahr
 /  mice and
found that Ahr
dbd/dbd mice are identical to Ahr
 /  mice in all of
these aspects, including a patent DV. The DV is a portal-
systemic shunt that connects the umbilical cord blood with
blood from both the portal vein and inferior vena cava
(Schermerhorn et al., 1996). This structure normally resolves
shortly after birth, yet remains open in Ahr
 /  mice. Similar to
Ahr
 /  mice, Ahr
dbd/dbd mice display a patent DV in addition to
a transient perinatal microvesicular steatosis in hepatocytes and
a 25% reduction in liver weight.
To determine whether Ahr
dbd/dbd mice are sensitive to
TCDD-induced toxicity, a number of classical toxic responses
to TCDD were also quantiﬁed. We observed that Ahr
dbd/dbd
mice failed to exhibit the obvious liver and thymic toxicity
normally associated with this dosing regimen. We also found
that similar to the Ahr-null, TCDD-induced cleft palate,
hydronephrosis, and intrahepatic lipid accumulation were
nonexistent in these mice.
Although the AHRdbd protein appears to be constitutively
nuclear in the absence of ligand, we showed previously that
a mutation introduced at the nuclear localization sequence also
causes abnormal liver development and renders mice resistant
to TCDD-induced toxicity (Bunger et al., 2003). Therefore, it
is unlikely that the cytosolic interactions lost due to localization
are important in the developmental or toxic phenotypes of these
animals, including those of cSrc, RelA, and pRB. Furthermore,
in combination with our previously reported observations on
Ahr
nls/nls mice, these results convincingly show that nuclear
localization alone is necessary but not sufﬁcient for Ahr to
function in development and toxicity. Therefore, sequestration
of ARNT within the nucleus as a mechanism of toxicity is
unlikely. However, we do not rule out the possibility that
Ahr
dbd/dbd mice may still show responsiveness to TCDD at
other endpoints not tested, such as tumor promotion.
We show here that AHR-mediated XME induction may be
directly related to a toxic response. Ahr
dbd/dbd mice express an
AHR that can be ligand-activated to form a heterodimer with
the ARNT protein in a similar manner to wild-type AHR, but
FIG. 7. TCDD-induced phenotypic changes in Ahr
dbd/dbd mice. (A)
Hepatomegaly (expressed as relative liver weight) and (B) thymic involution
(expressed as relative thymus weight) of DMSO- or TCDD-treated Ahr
þ/þ (n ¼ 10),
Ahr
þ/  (n ¼ 11), and Ahr
dbd/dbd (n ¼ 10) mice as quantiﬁed 6 days after
a single i.p. injection of p-dioxane (white bars) or 100 lg/kg TCDD (black
bars). *Indicates p < 0.001. (C) Intrahepatic lipid accumulation. Frozen
sections from DMSO- or TCDD-treated Ahr
þ/þ, Ahr
þ/ , and Ahr
dbd/dbd mice
were stained with Oil Red-O (lipids, red) and hematoxylin (nuclei, blue).
TABLE 1
TCDD-Induced Developmental Toxicity in Wild-Type and
Ahr
dbd/dbd Mice
Ahr-wt Ahr
dbd/dbd
Cleft palate DMSO 0% (n ¼ 6) 0% (n ¼ 8)
TCDD 29% (n ¼ 35) 0% (n ¼ 52)
Hydronephrosis DMSO 0% (n ¼ 6) 0% (n ¼ 8)
TCDD 100% (n ¼ 35) 0% (n ¼ 52)
Note. Pregnant dams were injected with DMSO or TCDD on ED10, and
litters were scored for the presence of cleft palate and hydronephrosis on
ED17–18. Incidence is expressed as a percentage.
90 BUNGER ET AL.cannot bind to DREs and activate XME expression. The fact
that these mice fail to exhibit a toxic response suggests that
DRE-driven gene expression is indeed upstream of the
physiologic effects of TCDD and that ARNT sequestration
may in fact not play a signiﬁcant role in the TCDD-induced
toxic endpoints assessed here. Furthermore, a developmental
phenotype of the Ahr
dbd/dbd mice consistent with that of Ahr
 / 
mice suggests that DRE-driven genes are also involved in early
liver development and vascular remodeling.
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